During the past decade, Karolinska Universitetssjukhuset, Huddinge conducted 50 clinical trials. In the 10-year time frame, 50 clinical trials started and 20 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 12 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Karolinska Universitetssjukhuset, Huddinge" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "Pfizer" with 6 trials sponsored, "Celgene" with 5 trials sponsored, "Takeda" with 4 trials sponsored and "Vertex Pharmaceuticals Incorporated" with 4 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 41 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Karolinska Universitetssjukhuset, Huddinge" #1 collaborator was "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator, "Karolinska Institutet" with 2 trials as a collaborator, "Linkoeping University" with 2 trials as a collaborator, "Uppsala University" with 2 trials as a collaborator and "AFA Insurance" with 1 trials as a collaborator. Other collaborators include 32 different institutions and companies that were collaborators in the rest 42 trials.

According to Clinical.Site data, the most researched conditions in "Karolinska Universitetssjukhuset, Huddinge" are "Multiple Myeloma" (8 trials), "Alzheimer's Disease" (6 trials), "Cystic Fibrosis" (4 trials), "Acute Myeloid Leukemia" (2 trials) and "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Karolinska Universitetssjukhuset, Huddinge" in a lesser frequency.

Most popular intervention types in "Karolinska Universitetssjukhuset, Huddinge" are "Drug" (53 trials), "Other" (10 trials), "Biological" (4 trials), "Device" (4 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "IVA" (4 trials), "ELX/TEZ/IVA" (3 trials), "Placebo (matched to ELX/TEZ/IVA)" (3 trials) and "Placebo (matched to IVA)" (3 trials). Other intervention names were less common.

The vast majority of trials in "Karolinska Universitetssjukhuset, Huddinge" are 68 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Karolinska Universitetssjukhuset, Huddinge". undefined are not yet recruiting, 13 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Karolinska Universitetssjukhuset, Huddinge, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Karolinska Universitetssjukhuset, Huddinge, 1 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 10 trials that are defined as “Not Applicable".